While data specifically addressing autoimmune populations are currently lacking, the potential of SGLT2 inhibitors to modulate endothelial dysfunction and low-grade systemic inflammation suggests they may also benefit patients with autoimmune-driven HFpEF. This evidence concerns the gene SLC5A2 and endothelial dysfunction.